# CollPlant Biotechnologies Ltd (CLGN)

Source page: https://stoqly.net/companies/clgn

- **Ticker:** CLGN (Nasdaq)
- **Sector:** Health Care / Orthopedic, Prosthetic & Surgical Appliances & Supplies
- **SEC CIK:** 0001631487
- **Latest annual report:** 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1631487/000121390026034393/ea0282912-20f_collplant.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $4.14 on 2026-10-30
- **Market cap:** $50.5M
- **EPS, trailing 12 months:** −$0.94
- **Revenue (FY2025):** $2.4M
- **Revenue growth:** +360.4%
- **Revenue growth, 5-year CAGR:** −17.3%
- **Gross margin:** 64.8%
- **Operating margin:** −484.3%
- **Net margin:** −484.6%
- **Free cash flow:** −$9.4M
- **Free cash flow margin:** −398.4%
- **Return on equity:** −117.6%
- **Change in share count:** +6.5%
- **Piotroski F-score:** 3/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/clgn/figures.csv

| US$ millions | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 5 | 2 | 6 | 16 | 0 | 11 | 1 | 2 |
| Operating income | -4 | -8 | -6 | 0 | -17 | -8 | -17 | -11 |
| Net income | -6 | -11 | -6 | 0 | -17 | -7 | -17 | -11 |
| Diluted EPS (US$) | 1.43 | -2.23 | -0.84 | 0.02 | -1.53 | -0.62 | -1.45 | -0.94 |
| Operating cash flow | -1 | -6 | -4 | 3 | -14 | -3 | -14 | -9 |
| Free cash flow | -2 | -7 | -5 | 1 | -15 | -4 | -15 | -9 |
| Cash | 5 | 4 | 3 | 13 | 30 | 27 | 12 | 6 |
| Debt and leases | — | 0 | 0 | 0 | 0 | — | — | — |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.